PL2020999T3 - Kompozycje zawierające alfa-ketoglutaran i ich zastosowanie do modulowania wydajności mięśniowej - Google Patents

Kompozycje zawierające alfa-ketoglutaran i ich zastosowanie do modulowania wydajności mięśniowej

Info

Publication number
PL2020999T3
PL2020999T3 PL07728341T PL07728341T PL2020999T3 PL 2020999 T3 PL2020999 T3 PL 2020999T3 PL 07728341 T PL07728341 T PL 07728341T PL 07728341 T PL07728341 T PL 07728341T PL 2020999 T3 PL2020999 T3 PL 2020999T3
Authority
PL
Poland
Prior art keywords
muscle performance
ketoglutarate
alpha
compositions
modulating muscle
Prior art date
Application number
PL07728341T
Other languages
English (en)
Inventor
Stefan Pierzynowski
Original Assignee
Sgp & Sons Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sgp & Sons Ab filed Critical Sgp & Sons Ab
Publication of PL2020999T3 publication Critical patent/PL2020999T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PL07728341T 2006-04-21 2007-04-20 Kompozycje zawierające alfa-ketoglutaran i ich zastosowanie do modulowania wydajności mięśniowej PL2020999T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PL379512A PL379512A1 (pl) 2006-04-21 2006-04-21 Nowe metody i ich zastosowanie
PCT/EP2007/053882 WO2007122190A1 (en) 2006-04-21 2007-04-20 Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance
EP07728341A EP2020999B1 (en) 2006-04-21 2007-04-20 Compositions comprising alpha-ketoglutarate and their use for modulating muscle performance

Publications (1)

Publication Number Publication Date
PL2020999T3 true PL2020999T3 (pl) 2012-01-31

Family

ID=38359362

Family Applications (2)

Application Number Title Priority Date Filing Date
PL379512A PL379512A1 (pl) 2006-04-21 2006-04-21 Nowe metody i ich zastosowanie
PL07728341T PL2020999T3 (pl) 2006-04-21 2007-04-20 Kompozycje zawierające alfa-ketoglutaran i ich zastosowanie do modulowania wydajności mięśniowej

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL379512A PL379512A1 (pl) 2006-04-21 2006-04-21 Nowe metody i ich zastosowanie

Country Status (9)

Country Link
US (1) US20090069429A1 (pl)
EP (1) EP2020999B1 (pl)
JP (1) JP2009534360A (pl)
CN (1) CN101426490B (pl)
AT (1) ATE522210T1 (pl)
DK (1) DK2020999T3 (pl)
ES (1) ES2372207T3 (pl)
PL (2) PL379512A1 (pl)
WO (1) WO2007122190A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014519483A (ja) * 2011-04-18 2014-08-14 ネステク ソシエテ アノニム α−ヒドロキシイソカプロン酸を含有する栄養組成物
ITBO20120226A1 (it) * 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
WO2016083399A1 (en) * 2014-11-24 2016-06-02 Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. Alpha-ketoglutarate in combination with glutamate dehydrogenase for treating hyperammonemia
CN106963749A (zh) * 2017-03-23 2017-07-21 华南农业大学 α‑酮戊二酸（盐）在抗疲劳和提高肌肉运动力量方面的应用
US11802103B2 (en) 2018-09-25 2023-10-31 Ponce De Leon Health Designated Activity Company Process of making calcium alpha-ketoglutarate
CA3142781A1 (en) * 2019-06-10 2020-12-17 Buck Institute For Research On Aging Methods and compositions for altering senescence associated secretory phenotype

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8704217D0 (sv) * 1987-10-29 1987-10-29 Vinnars Erik Ab Aminosyrakomposition for parenteral neringstillforsel
SE9303691D0 (sv) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
SE9402027D0 (sv) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
ITRM20010445A1 (it) * 2001-07-25 2003-01-27 Sigma Tau Healthscience Spa Alfa-chetoglutarati di principi attivi e composizioni che li contengono.
MXPA05013901A (es) * 2003-07-01 2006-03-09 Essentys Ab Uso de acido alfa-cetoglutarico para tratamiento de desnutricion o condicion de glucosa alta en plasma.

Also Published As

Publication number Publication date
CN101426490A (zh) 2009-05-06
CN101426490B (zh) 2011-01-12
DK2020999T3 (da) 2011-11-21
EP2020999B1 (en) 2011-08-31
US20090069429A1 (en) 2009-03-12
ATE522210T1 (de) 2011-09-15
EP2020999A1 (en) 2009-02-11
WO2007122190A1 (en) 2007-11-01
ES2372207T3 (es) 2012-01-17
JP2009534360A (ja) 2009-09-24
PL379512A1 (pl) 2007-10-29
HK1131340A1 (en) 2010-01-22

Similar Documents

Publication Publication Date Title
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
MY150602A (en) Subtituted-quinoxaline-type piperidine compounds and the uses thereof
WO2007092622A3 (en) Compositions and methods for treating bone
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
MX2010001460A (es) Composiciones y metodos para tratamiento de semillas.
MY153948A (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof
IN2012DN00624A (pl)
WO2007095050A3 (en) N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
MX2009000657A (es) Composiciones y metodos para el tratamiento de mucositis.
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
ZA200901037B (en) Pyrimidone compounds as GSK-3 inhibitors
WO2008156685A3 (en) Tendon stem cells
EA201200428A1 (ru) Композиция и способ для лечения ожирения
ATE538799T1 (de) Zusammensetzungen zur behandlung von haarverlust
ATE522210T1 (de) Zusammensetzungen umfassend alpha-ketoglutarat und ihre verwendung zur modulierung der muskelleistung
TNSN08506A1 (en) Substituted carboxamides
WO2008028003A3 (en) Denture care composition
SG169346A1 (en) Use of yeast flakes for treating and/or preventing hyperinsulinemia
PH12012501636A1 (en) 2-((r)-2- methylpyrrolidin -2-yl) -1h- benzimidazole -4- carboxamide crystalline form 1
PH12012500824A1 (en) Oral composition for treating oral malodor
MX2010003771A (es) Forma cristalina 2 - de 2 ((r)-2-metilpirrolidin-2-il)-1h-benzimid azol-4-carboxamida.
MX2009004633A (es) Composicion solida para tratamiento de agua.
WO2008021439A3 (en) Compositions and methods for treatment of cardiac hypertrophy